Work to develop a vaccine to protect against human immunodeficiency virus (HIV) has been underway for four decades but we still have no effective vaccine. Treatments have been developed that allow people infected with HIV to live long and healthy lives, but a vaccine could prevent new infections, affecting about 1.3 million people annually worldwide, and could potentially eradicate the disease.
Unfortunately, vaccine development has been plagued by challenges related to the evasive tactics of the virus, which mutates very quickly, and difficulties in obtaining a structure for the main envelope protein of the virus, Env, which was finally solved by electron microscopy and crystallography in 2013. HIV vaccine researchers have come to the conclusion that ideal vaccine immunogens designed to generate a protective immune response should elicit antibodies that can recognize HIV via a number of target sites on the Env protein. Broadly neutralizing antibodies to each of these sites have been identified in some people infected with HIV-1 and in some animal models but efforts to elicit this broad antibody recognition of the diverse HIV strains and subtypes in response to a vaccine have not been successful.
A recent study from a group at the Ragon Institute, Scripps Research Institute, Leipzig University, La Jolla Institute for Immunology, UC San Diego, Moderna, and Massachusetts Institute of Technology provides insights into antibody-based HIV vaccine development that could lead to the identification of vaccine immunogen candidates to elicit such broadly neutralizing antibodies.
Scripps Research investigators used resources of the National Institute of General Medical Science and National Cancer Institute Structural Biology Facility (GM/CA) at beamline 23-ID-B of the Advanced Photon Source (APS), a U.S. Department of Energy (DOE) Office of Science user facility at DOE’s Argonne National Laboratory.
The research started with the observation that a broadly neutralizing antibody called 10E8 has excellent HIV neutralization properties but does not recognize self-antigens. This is an undesirable feature, as earlier antibodies to this membrane-proximal external region (MPER) site did. During an immune response that leads to the development of antibodies, precursor B cells that make a certain type of antibody are activated by the antigen they recognize (e.g., a viral protein), undergo mutations that increase their affinity for the antigen, and then start expanding to produce more of these cells.
With 10E8, the researchers identified precursors of the antibody, before these affinity mutations, and engineered immunogens to specifically activate these rare 10E8-class precursor B cells. This technique is called germline targeting.
To test their new immunogens, the researchers created mice that express the 10E8-class precursor B cells, which are normally only found in humans. They found that these B cells were functioning normally in mice, but when they immunized the mice with an immunogen designed to activate their targeted 10E8-class precursors B cells, they didn’t see the expansion they had hoped for, even though they could show that the B cells had high enough affinity to be activated.
Read more on APS website
Image: Orientation of mature 10E8 Fab in relation to the MPER peptide (heavy chain, white; light chain, dark gray; MPER peptide, purple; top left) and surface rendering and positioning of the critical YxFW residues of HCDR3 (bottom left), representative GT10.2-10E8UCAH mAb in complex with a glycan-knockout (KO) version of 10E8-GT10.2 (heavy chain, yellow; light chain, dark gray; targeted MPER graft with GT mutations, purple; top center; structure aligned and oriented to the MPER peptide as in the top left) and designed binding pocket (green) and engagement of the GT10.2-10E8-UCAH mAb HCDR3 (yellow) compared to mature 10E8 HCDR3 (white; bottom center) and representative GT10.2-WT mAb in complex with 10E8-GT10.2 (heavy chain, red; light chain, dark gray; targeted MPER graft with GT mutations, purple; top right) and binding pocket (green; bottom right).